Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

JP Morgan Chase & Company (JPM)

JP Morgan Chase & Company (JPM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is Charles River Laboratories Stock Underperforming the Dow?

With a market cap of $9.5 billion, Charles River Laboratories International, Inc. (CRL) is a leading American contract research organisation (CRO) serving the pharmaceutical, biotechnology, government and academic sectors. The Wilmington, Massachusetts-based company provides preclinical and early-stage drug discovery, safety assessment, and laboratory services that support the development of new drugs, vaccines and medical devices. 

Companies worth between $2 billion and $10 billion are generally described as "mid-cap stocks." CRL fits right into that category. It benefits from a strong competitive position driven by its end-to-end preclinical drug development capabilities, market leadership in research models, and deep, long-standing relationships with pharmaceutical...

Fundamentals

See More
  • Market Capitalization, $K 871,178,240
  • Shares Outstanding, K 2,722,262
  • Annual Sales, $ 278,906 M
  • Annual Income, $ 58,471 M
  • EBIT $ 125,010 M
  • EBITDA $ 132,948 M
  • 60-Month Beta 1.08
  • Price/Sales 3.11
  • Price/Cash Flow 14.47
  • Price/Book 2.55

Options Overview Details

View History
  • Implied Volatility 24.47% (+0.38%)
  • Historical Volatility 25.83%
  • IV Percentile 58%
  • IV Rank 17.25%
  • IV High 58.06% on 04/08/25
  • IV Low 17.47% on 01/22/25
  • Expected Move (DTE 3) 5.11 (1.61%)
  • Put/Call Vol Ratio 0.96
  • Today's Volume 21,268
  • Volume Avg (30-Day) 59,048
  • Put/Call OI Ratio 1.05
  • Today's Open Interest 792,300
  • Open Int (30-Day) 754,328
  • Expected Range 311.29 to 321.51

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 4.93
  • Number of Estimates 9
  • High Estimate 5.11
  • Low Estimate 4.79
  • Prior Year 4.81
  • Growth Rate Est. (year over year) +2.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
292.81 +7.72%
on 11/21/25
322.88 -2.32%
on 12/15/25
+11.80 (+3.88%)
since 11/14/25
3-Month
290.54 +8.56%
on 10/22/25
322.88 -2.32%
on 12/15/25
+6.21 (+2.01%)
since 09/16/25
52-Week
202.16 +56.02%
on 04/07/25
322.88 -2.32%
on 12/15/25
+75.82 (+31.65%)
since 12/16/24

Most Recent Stories

More News
J.P. Morgan Asset Management Research Reveals Nearly Half of Plan Participants Carry Credit Card Debt, Reducing Retirement Readiness

Comprehensive study highlights the need for improved plan design and participant support to help with retirement security

JPM : 315.41 (-1.44%)
J.P. Morgan Asset Management's Private Equity Group Closes Global Private Equity Fund XII Above Target at $1.4 Billion

The fund will focus on the small and mid-market, granting investors access to top-tier GPs

JPM : 315.41 (-1.44%)
Is Charles River Laboratories Stock Underperforming the Dow?

Despite lagging the Dow Jones Industrial Average over the past year, Charles River Laboratories continues to attract cautious optimism from analysts regarding its longer-term outlook.

JPM : 315.41 (-1.44%)
$DOWI : 48,173.57 (-0.50%)
CRL : 195.95 (-1.11%)
LH : 260.10 (-1.23%)
JPMorganChase Declares Preferred Stock Dividends

JPMorgan Chase & Co. (NYSE: JPM) (“JPMorganChase” or the “Firm”) has declared dividends on the outstanding shares of the Firm’s Series CC preferred stock. Information can be found on the Firm’s...

JPM : 315.41 (-1.44%)
JPM : 315.41 (-1.44%)
J.P. Morgan Asset Management Launches Its First Tokenized Money Market Fund

Qualified investors gain access to on-chain assets through Morgan Money ®

JPM : 315.41 (-1.44%)
Chase Freedom® Introduces Q1 2026 Categories: Dining, Supporting the American Heart Association, and Norwegian Cruise Line

Freedom and Freedom Flex cardmembers can earn 5% cash back on new rotating, quarterly categories

JPM : 315.41 (-1.44%)
3 Finance Stocks to Buy on Rising 10-Year Treasury Rates

Rising 10-year Treasury rates are creating new opportunities in financial stocks. See why JPMorgan, Morgan Stanley, and Prudential could outperform in 2026

PRU : 116.88 (-0.61%)
JPM : 315.41 (-1.44%)
MS : 177.40 (-0.22%)
J.P. Morgan Arranges Landmark U.S. Commercial Paper Issuance on Solana Public Blockchain for Galaxy Digital Holdings LP

The transaction, completed on behalf of Galaxy, which also acted as the structurer, marks one of the first debt issuances ever executed on a public blockchain ...

JPM : 315.41 (-1.44%)
J.P. Morgan Asset Management Unveils New JPMorgan 100% U.S. Treasury Securities Money Market ETF (JMMF)

Fund marks the firm's entry into the rapidly evolving money market ETF space

JPM : 315.41 (-1.44%)
JMMF : 100.21 (+0.01%)
Jamie Dimon Has Long Been Sounding the Economic Alarm. After the Fed’s Latest Rate Cut, Can You Still Bank on JPMorgan Stock?

A nearly 5% plunge in JPM shares on Tuesday is reason for caution with the leader of U.S. bank stocks.

JPM : 315.41 (-1.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

JPMorgan Chase & Co. is one of the largest financial service firms in the world. JPMorgan organizes its business through five reportable segments: Consumer & Community Banking segment serves consumers and businesses through personal service at bank branches and through automated teller machine, online,...

See More

Key Turning Points

3rd Resistance Point 326.96
2nd Resistance Point 324.92
1st Resistance Point 322.47
Last Price 315.41
1st Support Level 317.98
2nd Support Level 315.94
3rd Support Level 313.49

See More

52-Week High 322.88
Last Price 315.41
Fibonacci 61.8% 276.76
Fibonacci 50% 262.52
Fibonacci 38.2% 248.28
52-Week Low 202.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar